RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DREYLING M
Collezione AOU Alessandria

Items : 13

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology. in Leukemia / Leukemia. 2026 Sep;40(9):1961-1967. doi: 10.1038/s41375-026-03036-8. Epub 2026 Jul 7.

2026
AOU Alessandria

Lippl J; Reinke S; Koch K; Oschlies I; Schrod S; Wolfseher L; Hüttl P; Huttner M; Beà S; Campo E; Ladetto M; Cogliatti S; Ehinger M; Rymkiewicz G; Tabanelli V; Rauert-Wunderlich H; Rosenwald A; Spang R; Hoster E; Dreyling M; Altenbuchinger M; Klapper W;

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. in Lancet (London, England) / Lancet. 2026 May 16;407(10542):1953-1967. doi: 10.1016/S0140-6736(26)00362-4.

2026
AOU Alessandria

Herhaus P; Wirths S; Meerten TV; Heß G; Jachimowicz RD; Kerkhoff A; Stilgenbauer S; Jiang L; Leppä S; da Silva MG; Shpilberg O; Vergote VKJ; Trneny M; Riise J; Mey U; Hutchings M; Walewski J; Jerkeman M; Giné E; Doorduijn J; Dreyling M; Hoster E; Ladetto M; Tix T; Unterhalt M; Schmidt C; Klapper W; Pott C; Stefani PM; et alii...

Marked survival gains in patients ? 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020. in Haematologica / Haematologica. 2026 May 1;111(5):1694-1704. doi: 10.3324/haematol.2025.288929. Epub 2025 Oct 30.

2026
AOU Alessandria

Jiang L; Ladetto M; Hermine O; Kluin-Nelemans JC; Walewski J; Doorduijn J; Vergote V; Giné E; Jerkeman M; Hutchings M; Trneny M; Mey U; Riise J; Shpilberg O; Da Silva MG; Ribrag V; Schmidt C; Klapper W; Unterhalt M; Dreyling M; Hoster E;

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2026 Jul 14:JCO2600705. doi: 10.1200/JCO-26-00705.

2026
AOU Alessandria

Ladetto M; Gutmair K; Tavarozzi R; Pawlikowski A; Schomaker M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote VKJ; Horowitz NA; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Heß G; van Meerten T; Wirths S; Herhaus P; Novak U; Dierlamm J; Hänel M; Hanoun C; et alii...

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial. in Leukemia / Leukemia. 2026 Jan;40(1):95-105. doi: 10.1038/s41375-025-02787-0. Epub 2025 Nov 3.

2026
AOU Alessandria

Ladetto M; Brüggemann M; Baldus CD; Giné E; Visco C; Gameiro P; Doorduijn J; da Silva MG; Medina Herrera A; van der Velden VHJ; Homburg CHE; Sanz RG; Verhagen OJHM; Laqua A; Alessandria B; Ferrero S; Genuardi E; Khouja M; Schmidt C; Dreyling M; Jiang L; Hoster E; Darzentas N; Pal K; Chitadze G; Stewart JP; Gonzalez D; Pott C;

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. in Lancet (London, England) / Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2.

2024
AOU Alessandria

Dreyling M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote V; Shpilberg O; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Celli M; Hess G; Arcaini L; Visco C; van Meerten T; Wirths S; Zinzani PL; Novak U; Herhaus P; Benedetti F; Sonnevi K; Hanoun C; et alii...

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). in Leukemia / Leukemia. 2023 Sep;37(9):1887-1894. doi: 10.1038/s41375-023-01977-y. Epub 2023 Jul 26.

2023
AOU Alessandria
AOU Città della Salute di Torino

Hoster E; Jerkeman M; Ferrero S; Ladetto M; Klapper W; Evangelista A; Unterhalt M; Rosenwald A; Kluin-Nelemans HC; Schmidt C; Jiang L; Hermine O; Dreyling M; Scheubeck G;

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma. in HemaSphere / Hemasphere. 2021 Apr 21;5(5):e559. doi: 10.1097/HS9.0000000000000559. eCollection 2021 May.

2021
AOU Alessandria

Ladetto M; Dreyling M;

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26.

2021
AOU Alessandria

Seymour JF; Herfarth K; Tonino SH; Ladetto M; Salles G; Ghielmini M; Rule S; Dreyling M; Jerkeman M;

A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. in Future oncology (London, England) / Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28.

2021
AOU Alessandria

Romano A; Novotny W; Co M; Huang H; Ladetto M; Smith SD; Wang M; Tam CS; Dreyling M; Holmgren E; Huang J; Gouill SL;

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):188. doi: 10.3390/cancers14010188.

2021
AOU Alessandria
AOU Città della Salute di Torino

Hermine O; Vitolo U; Guarini A; Fabbri A; Patti C; Latte G; Spina M; Pascarella A; Vallisa D; Merli F; Di Renzo N; Cabras MG; Moia R; Volpetti S; Tani M; Del Giudice I; Barbero D; Ghislieri M; Drandi D; Genuardi E; Evangelista A; Passera R; Hoster E; Ferrero S; Zaccaria GM; Kluin-Nelemans HC; Cortelazzo S; Dreyling M; Ladetto M; et alii...

EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas. in HemaSphere / Hemasphere. 2020 Mar 11;4(2):e351. doi: 10.1097/HS9.0000000000000351. eCollection 2020 Apr.

2020
AOU Alessandria

Ladetto M; Dreyling M;

Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. in HemaSphere / Hemasphere. 2020 Apr 3;4(2):e347. doi: 10.1097/HS9.0000000000000347. eCollection 2020 Apr.

2020
AOU Alessandria
AOU Città della Salute di Torino

Hermine O; Dreyling M; Cortelazzo S; Ribrag V; Eckert C; Abdo C; Callanan M; Jimenez C; Ciabatti E; Bomben R; Starza ID; Cheminant M; Villarese P; Mantoan B; Genuardi E; Ferrante M; Zaccaria G; Lhermitte L; Söhlbrandt A; Benmaad I; Alcantara M; Drandi D; Delfau-Larue MH; Pott C; Ladetto M; Ferrero S; Macintyre E;